Orgenesis Chief Science Officer Describes Science in Two Online Publications

WHITE PLAINS, N.Y.-- Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, was featured in two online publications during the week of June 11.

Sarah Ferber, Ph.D., Chief Science Officer of Orgenesis, contributed a guest column to the June 11 edition of Clinical Leader. Titled “Using a Diabetes Patient’s Own Liver Cells as a Novel Source of Insulin,” the column outlines the autologous cell replacement therapy for diabetes patients currently under development at the Company.

Dr. Ferber also contributed a bylined article to the June 15 edition of BioMedReports with the same title and focus.

Jacob BenArie, President and Chief Executive Officer of Orgenesis, was interviewed last week by Joseph Sherman, writer of the “Start Up Nation” feature at the website United with Israel. Mr. BenArie shared his thoughts on the challenges of developing Orgenesis’ technology. A published article is expected in a few weeks.

To read the Clinical Leader article in its entirety, please visit:

To read the BioMedReports article in its entirety, please visit:

About Orgenesis Inc.

Orgenesis (OTCBB: ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit:

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

On Behalf of the Board
Orgenesis Inc.

Vered Caplan, Chairperson

Investor Relations:
Crescendo Communications, LLC
David Waldman, +1-877-560-9060

Source: Orgenesis Inc.